
MJF Newsletter May 2021





3D render of a monoclonal antibody (mAb or moAb) – an antibody made by cloning a unique white blood cell.

ASHA LEADS FUNDRAISING FOR COVID-19 IN INDIA

For the past several weeks, from her home in Silicon Valley, Asha Jadeja Motwani has been leading her foundation's efforts towards the fight against Covid-19 in India. As well as fundraising and pledging \$1 million in matched funds for the crisis, Asha has rallied together with leading Indian American's to support efforts to combat the ravages of Covid-19 in India, contributing to regulatory approval that is beginning to save lives.

Breakthrough in the Monoclonal Antibody Treatment

After months of bureaucratic hurdles regarding the approval of key vaccinations for the people of India, Asha has personally lobbied at the highest levels to get the Indian government's approval of the monoclonal antibody vaccination. Her pressure resulted in 100,000 doses being acquired through a generous donation from healthcare company, Roche. Asha was driven by the conviction that if these doses of monoclonal antibodies can be administered in the next few days it could potentially save a hundred thousand lives. We now know that vaccinations are crucial in protecting the most vulnerable from serious illness and death, and for stopping the spread of the virus and new variants.

Every day is crucial in the fight against Covid-19 in India and Asha has also rallied the support and cooperation of multiple companies in India, from Google India, to pharmaceutical company, Regeneron, and healthcare pioneers, Roche. In her quest for faster action at the policy and ground level, Asha spoke to the biopharmaceutical company founder, Kiran Mazumdar Shaw, and renowned Indian-American physician, Sidd Mukerjee, in an effort to combat the crisis through mobilizing those in power in New Delhi. So far, the communities' efforts have inspired hundreds of people in the Indian American diaspora to get involved in supporting efforts to help get India through this devastating wave of the pandemic.





"We were pulling our hair out, because we knew that every hour it was delayed, meant lives lost."

ASHA JADEJA

"We could have had this moment in December 2020, or even earlier" BARKHA DUTT

Asha Discusses the Monoclonal Antibody Treatment with Barkha Dutt

This live video broadcast illustrates how effective the Monoclonal Antibody Treatment has been, showing how it helped its first patient in India, 84-year-old patient Mohabbat Singh in Medanta, Gurugram. As his doctor, Dr. Arvinder Soin at Medanta Hospital said on the programme:

"Since we had the approval and since we had the Monoclonal Antibodies, we administered them to him and he was observed for a day and then he was discharged. It's too soon to tell if he's going to be absolutely well, but so far he's doing well."

Dr Trehan, meanwhile, explained that, *"If given in the first seven days, 70-80% of (high risk) patients avoid hospitalization,"* but revealed that originally there were bureaucratic problems in acquiring the drugs, as the Modi Government had refused authorization for the Monoclonal Antibody Treatment in December 2020. There were also logistical issues that had to be overcome, such as streamlining testing, assessment, treatment and distribution so that high risk patients could be treated in the first week of the illness, when it would be most effective.

Speaking about Asha's campaigning on the programme, Barkha Dutt explained how Asha lobbied for authorization and secured the free 100,000 doses from Roche, so that all Indians would have access to treatment rather than only the most powerful and wealthy, through diplomatic privileges.

Asha herself spoke on the programme about her frustrations in receiving the authorization for treatment and distribution in India. Asha then discussed how these efforts were eventually successful through cooperation and generosity of key companies and individuals in India and its diaspora.

Further Success of Monoclonal Antibody Therapy

As reported by NDTV, there has been further "successful use of the Monoclonal antibody in two Covid patients with fast progression of symptoms within the first seven days". At Sir Ganga Ram Hospital of New Delhi, two patients recovered and were discharged within 12 hours, including a 36-year-old healthcare worker and 80-year-old R K Razdan who was diabetic and presenting serious symptoms. Both patients recovered and were discharged within 12 hours, proving the efficacy of the treatment.

Dr Pooja Khosla, a senior consultant of the Department of Medicine at Sir Ganga Ram Hospital said, "Monoclonal antibodies could prove to be a game-changer in times to come if used at an appropriate time. It can avoid hospitalisation in highrisk groups and progression to severe disease. It can help escape or reduce the usage of steroids and immunomodulation which would further reduce the risk of fatal infections like Mucormycosis, secondary bacterial and viral infections like CMV... The awareness about early identification of high-risk category in our population and timely therapy with Monoclonal antibody as day care treatment may reduce the burden of cost on the healthcare sector."

Live video broadcast shows how effective the Monoclonal Antibody Treatment has been, showing how it helped its first patient in India, 84-year-old patient Mohabbat Singh in Medanta, Gurugram.



1st Monoclonal Antibody Therapy Administered at Medanta, Gurugram

Our communities inside and outside of India have much more to do, still. With over 350,000 deaths so far, and over 29 million cases in total, the more we in the Indian diaspora can do to help, the better. Through the charitable Motwani Jadeja Foundation Family Trust, Asha continues to lead the effort and sustain progress in the region, and welcomes further involvement, cooperation and fundraising.

DONATE NOW

Furthermore, as many as 40 Covid patients have taken a singledose drug cocktail of monoclonal antibodies at Hyderabad's Asian Institute of Gastroenterology, according to NDTV. *"In* 24 hours, they recovered from clinical symptoms like fever, malaise etc.," said chairperson of the hospital, Dr Nageshwar Reddy. Hyderabad-based Asian Institute of Gastroenterology is carrying out one of the largest studies to find out if the therapy is effective against the highly infectious Delta variant." Studies from the US have shown that this is effective against the British, Brazilian and South African variants. No one has tested it against the Delta variant we have here. So we are in parallel testing whether it is effective against the mutant virus. Results that we have now in 40 patients who we analysed after one week. In almost 100% of cases, the virus disappeared when we did RT-PCR," said Dr Reddy.



The Fight Against Covid-19 is Not Over!

India Covid-19 Support by Motwani Jadeja Family Foundation, matching grants.

Areas

- · Sequencing of new variants
- Emergency training of nurses
- Temporary safe spaces for children orphaned in second wave.

Motwani Jadeja Family Foundation, a USA 501c3 has allocated US\$ 1 million in matching funds towards long and medium term medical efforts. Your generous donation will accelerate ongoing effective interventions, continue to save lives for months to come and create protections for Wave 3.

Where will your donation go?

After a lot of research and conversations with experts on the ground we have decided to dedicate our funds towards 3 critical areas:

• Sequencing of new Covid-19 variants in India by two credible institutions in India

www.mjf.world • www.ashajadeja.world • www.rcf.world

- Training of ER nurses across India and
- Temporary safe spaces for children orphaned in second wave

Double Your Tax Free Donation

Motwani Jadeja Family Foundation

US Tax ID 46-2186408 Address 543 Center Dr. Palo Alto. CA. 94301 USA





@motwani_jadeja @ashajadeja325





/motwanijadeja